Drug Discovery
Diagnostics, Drug Development, Drug Discovery, Featured, SDBN Blog »
San Diego’s Biotechnology Companies: Who’s Taking Off? |  |
|
Posted by Lara March 8th, 2012 .
| |
| No Comments |
Image Courtesy Flickr User JoF
Updates to San Diego Biotechnology Company Directory
| Company | Status | Details |
|---|---|---|
| 1060 Discovery Engineering | Added | |
| Adnavance | Removed | |
| ALARIS Medical Systems | Removed | Now under Cardinal Health |
| Alere | Added | Acquired Biosite |
| Altair Therapeutics | Removed | Shut down |
| Amira Pharmaceuticals | Removed | Acquired by Bristol-Myers Squibb |
| Amplyx Pharmaceuticals | Added | |
| Aperio | Added | |
| Applied Proteomics | Added | |
| Aragon Pharmaceutical | Added | |
| Astute Medical | Added | BioSite spinoff |
| AvantGen | Added | |
| Avelas Biosciences | Added | |
| Azco Biotech, Inc. | Added | |
| Balboa Bio | Removed | |
| Bio Applied Technologies Joint, Inc. | Added | |
| BioAtla | Added | |
| Biocept | Added | |
| BioLaurus | Added | |
| BioMedica, Inc. | Removed | |
| BioSettia | Added | |
| BioSite | Removed | Acquired by Alere |
| Biotix | Added | |
| BPS Bioscience, Inc | Added | |
| Calmune Corporation | Removed | |
| Carolus Therapeutics | Added | |
| Cebix | Added | |
| Crinetics | Added | Started by ex-Neurocrine employees |
| CryoCor, Inc. | Removed | |
| Diverse Diagnostics | Removed | |
| Dx Innovations | Removed | |
| Elcelyx | Added | |
| Enigma diagnostics | Added | |
| Essentialis | Added | |
| Etaluma | Added | |
| EuMederis Pharmaceuticals, Inc. | Added | |
| Expedeon | Added | |
| Genetex | Added | |
| Genofi | Added | |
| GenTarget Inc, | Added | |
| GenVault | Added | Existing, missed in original directory |
| Harbor Biosciences | Added | Changed name from Hollis Eden |
| Helixis | Removed | Acquired by Illumina |
| HemaQuest | Added | |
| Hollis-Eden | Removed | Changed name to Harbor Biosciences |
| Iapyx Medical | Removed | |
| Icx Biosystems | Removed | |
| IDM Pharma, Inc. | Removed | Acquired by Takeda 2009 |
| Inception Sciences | Added | Amira spinoff |
| Inhibrx | Added | |
| KFx Medical, Inc. | Removed | |
| Kinagen, Inc. | Added | |
| Kinexis, Inc. | Removed | |
| Kyowa Hakko Kirin California, Inc. | Added | |
| LeGene Biosciences | Added | |
| LiquidGrids | Added | Previously known as Swarmology |
| MabPrex.com | Added | |
| MediVas LLC | Removed | |
| Metabasis Therapeutics, Inc. | Removed | |
| MO BIO Laboratories | Added | Existing company missed in original directory |
| Molecular Response | Added | |
| Mpex Pharmaceuticals | Removed | Name change to Rempex |
| Nacalai usa | Added | |
| NeoMPS, Inc. | Removed | Now part of PolyPeptide Group |
| NeuroGenetic Pharmaceuticals Inc. | Added | |
| Novalar | Removed | |
| Nventa | Removed | Merger with Akela Pharma, Inc March 27, 2008 |
| Oceanside Pharmacuticals | Added | |
| Orbigen | Removed | |
| ORQIS Medical Corporation | Removed | |
| PAGEgel, Inc. | Removed | Merged with Expedeon/Protein Discovery |
| Paramount BioSciences, LLC | Removed | |
| Pegasus Cleanroom Services | Added | |
| Perry Scientific | Removed | Acquired by Absorption Systems |
| Pfenex | Added | |
| PharmaCircle | Added | |
| Phenometrics | Added | |
| Phenomix | Removed | |
| PliCare Therapeutics | Added | |
| ProteinLabs | Added | |
| Rebexsess | Added | |
| Rempex Pharmaceuticals | Added | Name change from Mpex |
| Renascions | Added | |
| SeaSpine | Added | |
| Serametrix | Added | |
| SG Biofuels | Added | |
| SGX Pharmaceuticals, Inc. | Removed | As of 2008, acting as subsidiary of Lilly |
| Sidney Kimmel Cancer Center | Removed | |
| Sonexa Therapeutics | Added | |
| SorrentoTherapeutics.com | Added | |
| Sova Pharmaceuticals | Added | |
| Strategic Enzyme Applications | Added | |
| Tanox | Removed | |
| TargeGen, Inc. | Removed | Acquired by Sanofi-Aventis |
| Targeson Inc | Added | |
| Theragence Inc. | Added | |
| TheraKem | Removed | |
| Torrey Path, LLC | Removed | |
| TorreyPines Therapeutics | Removed | |
| TrovaGene | Added | |
| Tulip BioMed, Inc. | Removed | |
| Ultimate Labs | Added | |
| Vasgene | Removed | |
| Verus Pharmaceuticals, Inc | Removed | |
| ViaCyte Technologies: Stem Cell Engineering | Added | |
| VivaMab, LLC | Added | |
| West Wireless Health Institute | Added | |
| Zacharon Pharmaceuticals | Added |
A recent report suggests evidence that the San Diego biotech scene is going strong. Released in December 2011 the Life Sciences Cluster Report by Jones Lang LaSalle rates San Diego #7 in the global biotech clusters. The report examines global locations for viable industry hubs, and defines a “cluster” by a multiple data points including:
- Educated workforce
- Venture and investment capital
- Centers of excellence and innovation
- Industry-friendly political structures
- Institutions of higher learning
- Target economic development incentives
- Patent protection
- Other associations and supporting infrastructure
Ranking in the top 10 for funding – third in VC and sixth for NIH funding – it seems that the money is rolling in for San Diego. The 97-page study says San Diego’s dense concentration of incubator and start-ups is expected to continue growth in the near future.
Each of the submarkets reviewed – UTC, Torrey Pines, Sorrento Mesa, and Sorrento Valley – experienced growth in 2011, aside from Sorrento Mesa being almost completely leased. The report forecasts continued recovery in rents, vacancies tightening and, due to a lack of new development, re-positioning of older properties to meet demands for higher quality facilities, particularly in Sorrento Mesa.
Additionally, Torrey Pines, San Diego’s largest submarket, has seen a resurgence of growth, with more life science companies acquiring larger spaces. The report states that in 2011 Verenium signed a deal larger than Torrey Pines has seen in two years.
NIH grants have increased 28 percent from 2010 and by 70 percent from 2008. The outlook is sunny for San Diego in 2012, with a continued increase expected in the number of start-ups and dispersal of capital from venture capital and government funds.
A PDF of the complete report can be downloaded here.
Thanks to Flickr user JoF for this image of gliders taking off and landing at Torrey Pines, where many San Diego life science companies also ‘take off.’
More...Drug Development, Drug Discovery, Headline, SDBN Blog, SDBN Events »
SDBN March 26th 2012 Event with Organovo |  |
|
Posted by Mary Canady March 6th, 2012 .
| |
| No Comments |
Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been included in the MIT Technology Review’s 2012 TR50 list of the world’s most innovative companies. The excitement around Organovo has grown since they recently announced funding and their stock is now publicly traded. You’ll get the chance to hear from CEO Keith Murphy at our March 26th event, he’ll give a presentation titled ‘3D Bioprinting – Delivering Tissue on Demand for Drug Discovery & Development.’
At this event, we will delve into innovation and how it happens. What does it take to make an outstanding product – a game changer? We all have ideas but how does an idea get to be a reality? What are the barriers to innovation? It’s not just time, money and people. It’s even how you think about the problem.
We have two companies that are innovating to success:
Organovo, the featured company, will discuss how they overcame barriers to achieve an industry changing technology that still seems futuristic and impossible – printing tissue.
Invetech, the event sponsor, helps people translate their ideas into products. They will share a few key learnings of how to approach innovation.
We want to hear from the local innovators at this event,
- Do you have an idea but are stuck?
- How have you been successful in innovation?
- What barriers are in your way?
We’re having a contest to see who has the best idea for improving innovation in San Diego. During registration, or on LinkedIn or Twitter (tag with #Invetech), complete this statement: “My innovation idea is ______.” It can be a product idea or a general idea to improve the innovation culture in San Diego. We’ll discuss and vote on the best idea for innovation at the event and the winner will get two free passes to an SDBN event and a $15 gift card to Green Flash Brewery.
Sponsors
Premier
 |
Invetech is a contract product development and manufacturing consultancy working with companies worldwide. We provide a range of instrument, medical device and consumables development and manufacturing services that develop break-through products and solve complex automation challenges. With over 200 in-house specialists and experience drawn from over 5,000 projects, we work with medical device, clinical diagnostics, life sciences and drug discovery companies. Operating from locations in North America, Europe and Asia Pacific, our clients range from start-ups through to multinationals. Our proven design, engineering and manufacturing processes deliver shorter time-to-market, reduced risk, and enhanced product quality.
If you’re interested in sponsoring this event, please contact us.
Event Details
Who: Biotechnology professionals in the greater San Diego area
What: SDBN March 26th Event with Organovo
When: Monday, March 26th 2012, 5:30-8:30 p.m.
Where: Green Flash Tasting Room, 6550 Mira Mesa Boulevard, San Diego, CA 92121 (Directions below)
Cost: $25/20 (Academic), dinner provided, beverages for purchase (30 Green Flash beers on tap, soda), complimentary water.
Contact: http://sdbn.org/contact
For more information about the event: http://sdbn.org/marchevent
Directions: From the west: From the 805 North or South exit Mira Mesa Blvd, head east for 2.0 miles, the Green Flash Tasting Room will be on the left/north side of the street at Flanders Drive. From the east: From the 15 North or South exit Mira Mesa Blvd, head west for 3.6 miles, the Green Flash Tasting Room will be on the right/north side of the street at Flanders Drive.
Parking: The Green Flash lot holds about 70 cars, so come early and carpool if you’d like to park there. You can also park on the street, but be very mindful that there are some poorly marked ‘no parking’ areas, especially on Sequence where there is a center lane.
Biotechnology, Conferences, Drug Discovery, Featured, SDBN Blog »
Focus on San Diego: Life Science Conferences Spring 2012 | |
|
Posted by Mary Canady January 31st, 2012 .
| |
| No Comments |
Image courtesy of user leighty (Ryan Leighty) on Flickr
This spring San Diego downtown will be buzzing with scientific discussions as our city hosts a number of major scientific symposia. We are excited to attend and soak in all the science that will be shared during these two months. Our own Mary Canady will also be participating in a panel discussing on the triumphs and trials of Transitioning from Academia to Industry at the Annual meeting of the Biophysical Society on Tuesday, February 28, 2:30 PM – 4:00 PM.
We hope that you are planning on attending at least some of these events, and to help you plan your attendance, we outline below pertinent information about each conference:
| Name | Date | LinkedIn event page | Twitter account | Twitter hashtag | Tweetup or Event |
|---|---|---|---|---|---|
| 2012 Society for Laboratory Automation & Screening | 2/4- 2/9 | http://linkd.in/uVMlgx | @SLAS_org | #SLAS2012 | No* |
| Biophysical Society 56th Annual Meeting | 2/25- 2/29 | http://linkd.in/uwFbH6 | @BiophysicalSoc | #bps12 | No* |
| IBC’s Biopharmaceutical Development & Production Week | 2/27- 3/2 | http://linkd.in/rZVttm | @ibcusa | #BDPWeek | No* |
| American Chemical Society | 3/25- 3/29 | http://linkd.in/AgWH30 | @ACSNatlMtg | #ACSSanDiego | Follow @pidgirl for details |
| Experimental Biology | 4/21- 4/25 | http://linkd.in/taE6N6 | @expbio | #EB2012 | TBD |
*SDBN may host a tweetup if none will be planned by meeting organizers. Stay tuned.
The spring will be exciting for science in San Diego, add our Google calendar to yours so you won’t miss out on any local events. We hope you can set aside some time to take advantage of the presence of these major conferences in our city, we’ll be posting updates if you can’t. Some of the conferences have free or reasonable exhibit hall passes, and we’ll also post after hours events on our Facebook page so you can do some networking.
Comprendia is giving free social media consultations for your life science business, contact us to schedule one while you’re in San Diego.
More...Drug Development, Drug Discovery, News, Syndication, Xconomy »
A Sweet Deal: How Amira Reinvented Itself as a Drug Discovery Engine |  |
|
Posted by sandiegobiotech December 23rd, 2011 .
| |
| No Comments |
[[Click headline to continue reading.]]
Drug Discovery, News, Syndication, Xconomy »
Sanford-Burnham Joins Fold at Pfizer’s Centers for Therapeutic Innovation | |
|
Posted by sandiegobiotech November 3rd, 2011 .
| |
| No Comments |
[[Click headline to continue reading.]]
Drug Discovery, Featured, SDBN Blog, Uncategorized »
Virtual Biotech Part 1: What We Learned About Effectively Outsourcing a Drug Discovery Program | |
|
Posted by Lara July 28th, 2011 .
| |
| No Comments |
The first in our Virtual Biotech series, our July 19th event was a success. Thanks to our participants – some of San Diego’s leading virtual drug discovery scientists and CROs – for sharing their valuable insights and advice for scientists managing or considering how to manage an outsourced drug discovery project.
We’ve compiled some of the key tips and highlights of the night including:
- What activities should you outsource?
- Finding the right CRO for your objectives
- Managing your CRO relationship successfully every time
- Virtual tools to help manage and build your CRO network
- Finding the funding and resources you need for your virtual drug discovery projects
What Activities Should You Outsource?
Our panelist Scott Struthers, Founder & CSO of Crinetics Pharmaceuticals, summed up this topic with a simple, “…what you’re good at, you do in-house; what you can afford you do in-house.”
Struthers’ team looks to outsourcing when dealing with capital- or labor-intensive projects and this was the consensus among panel members. By focusing on the activities your team does best, your efficiency and productivity are maximized – all else can be outsourced.
Finding a CRO to Become Part of Your R&D Network
Finding a CRO you can trust is critical. Here are some tips and practices from our panelists for finding the perfect CRO for your project:
- Seek recommendations from colleagues and friends. Whether referrals are from scientists within your long-term network or a colleague in your current company, peer reviews are incredibly valuable for obvious reasons. These recommendations can also help you distill your initial CRO options down to a few, making the search more manageable.
- Leslie Hickle, VP Business Development at BioAtla, LLC, identified the following three key areas to consider when determining if a CRO will be a fit for your project:
- Quality – Do they have referrals?
- Cost – Are their services cost-effective for this project?
- Speed – Do they deliver on time?
Hickle also notes that you will need to clearly determine your own expectations for each of these categories so you can easily compare CROs.
- Once a CRO is a fit, never, ever, ever – ever – let them go. They are now part of your Virtual R&D Network.
Managing Successful CRO Relationships
While several elements comprise a successful strategy when managing a CRO, this statement truly sums up the hallmark characteristic of successful, long-term CRO relationships:
“…the really successful projects are the ones where we become like an extension of the project team, where we’re looked on as collaborators.”
- Panelist Diana Wetmore, Vice President of Business Development at Emerald BioStructures
Manage your CRO relationship as if it were another branch of your existing team. Speakers note that this extends to all areas of a project. To successfully manage a CRO relationship, a strategy is required that consists of:
- Partnership – Viewing your CRO as a member of your team will optimize your project’s productivity and overall success; CROs will give you input and documentation to help you with your budget, your strategy, and many other areas of your project.
- Communication -
- High frequency especially at the beginning of a project is important
- Milestones and goals are clearly identified so no grey area exists
- Virtual tools are extremely helpful throughout the entire project, and online video tools were identified as especially useful when establishing a new relationship
- Problems or issues are communicated and handled as team
- Dedicated Management – A dedicated person who manages the virtual meeting and collaboration process is essential. This person leads and organizes the virtual meeting space, including: communications, coordinating attendee schedules, managing the call itself, gathering and sharing any relevant documents, following up with attendees, tracking the project and managing online communication platforms for team
- Alignment – Be On the Same Page: To achieve success, both the CRO and the client need to be on the same page. Know what you want and expect, and have the conversations early to establish the foundation for your relationship and ensure consistent successes.
Global or Local?
Resoundingly, the quality of the relationship, not where the CRO was located, seemed to be the most important ingredient. However, here are some pros and cons of global vs. local CROs listed by our participants:
Global Pros
|
Global Cons
|
Local Pros
|
Local Cons
|
Best Virtual Tool to Help Manage Outsourcing
Participants appreciated the abundance of online tools and resources available to help build their global networks of outsourced R&D. Useful tools included:
- Virtual meeting spaces – Online video and audio programs allow easy, inexpensive, and (most importantly) frequent communication.
- Virtual file-sharing spaces - Sharing content quickly and securely helps to increase efficiency
How to Find Funding and Resources
Our participant, Jim Hauske, President and Founder of Sensor Pharma, notes four key questions that need to be answered to obtain funding, or the possibility of funding:
- Who owns the company?
- What is the therapeutic, or technology focus?
- What, if anything, has been accomplished?
- What is the IP estate?
And where to find that funding?
- VCs
- Pharma
- SBIR grants (Small Business Innovation Research) – low hurdle for startups
- Disease organizations
- Patient Advocacy groups
- High net worth individuals and their non-profit organizations
- Self funded
- Micro-funding (individuals, small private groups)
Resources: In addition to finding funding, resources are available for virtual drug discovery companies, such as San Diego Entrepreneur’s Exchange. SDEE is a virtual incubator and social networking tool for San Diego startups. This site allows scientist’s access to resources such as equipment and lab space and helps teams find other scientists with which to collaborate and potentially partner.
How are “risk sharing” deals really structured?
CROs can help to shoulder some of the risk involved with a project. For example, Diana Wetmore explained that her CRO may determine the structure of a risk-sharing deal by assessing a project, then binning into one of three levels – low- , mid- , and high-risk projects. Varying levels of commitment are proposed by the CRO, according to perceived probability of success.
In an extreme example of sharing the risk burden Richard Lin, moderator and President and CEO of Explora BioLabs, emphasized flexibility and creativity when assessing a risk-sharing deal. He explained that his CRO performed an entire project for no fee, and received double the normal payment when the client achieved Phase I funding – a risk, but a clear win for both sides.
Bottom Line
You and your CRO are on the same team. Utilize your network and online tools to find your CRO. Then build a successful relationship by defining your expectations, communicating frequently, and including your CRO partner in all processes along the way.
We hope these tips and practices will help you to effectively manage your Drug Discovery outsourcing.
If all of your questions weren’t answered here, stay tuned for more in our Virtual Biotech series or leave a question or comment below.
Or, are you a CRO or virtual drug discovery scientist with some insights our community could use? We’d love to hear from you!
Thanks to Our Virtual Drug Discovery Participants:
Jim Hauske, President and Founder,Sensor Pharma (Bio)
Virtual Drug Discovery panelists:
Leslie Hickle,VP, Business Development, BioAtla, LLC (LinkedIn)
Daniel Holsworth,Co-founder/Board of Directors, ODIN Therapeutics AS(LinkedIn)
Richard Lin (Moderator), President and CEO, Explora BioLabs (LinkedIn)
Ajay Madan, Senior Director of Development, Neurocrine Biosciences (LinkedIn)
Scott Struthers, Founder & CSO,Crinetics Pharmaceuticals (LinkedIn)
Diana Wetmore, Vice President of Business Development, Emerald BioStructures (Bio)
More...Drug Discovery, News, Syndication, Xconomy »
Organovo’s Bio-Printing Technology Yields Unanticipated Revenue from Pharma Partners | |
|
Posted by sandiegobiotech July 13th, 2011 .
| |
| No Comments |
[[Click headline to continue reading.]]
Drug Discovery, Headline, SDBN Blog, SDBN Events, Uncategorized »
SDBN July 19th Event: Virtual Biotech Part 1: How to Effectively Outsource a Drug Discovery Program | |
|
Posted by Mary Canady July 1st, 2011 .
| |
| No Comments |
Changes in the drug discovery landscape have presented many tough challenges for our region, including downsizing for larger companies and a dearth of VC funding for startups. With these challenges come opportunities, however, because drug companies are hungry for drug candidates to fill their pipelines. Additionally, the abundance of drug discovery contract research organizations (CROs), the ability to manage them remotely, and the ability to find partners and tools more easily on the internet presents an interesting opportunity.
Our July 19th event is our first in a series of Virtual Biotech events this year, and we’ve brought together those who have successfully outsourced drug discovery programs as well as some of the CRO providers. We’ve asked them to discuss the ‘howtos’ of managing an outsourced drug discovery project, and we think they’ll have some great insights, both at a high level and in the day to day details of the processes. In this hands-on event, we’ll take questions from you beforehand so that the resulting presentation and discussions will benefit you the most, and we’re open to what we should cover in future events. In addition, at this event some of our CRO sponsors will be providing credit for services at the event so we’re hoping you go home with some great deals for your projects. Register here.
| Time | Activity | Participants |
|---|---|---|
| 5:30-6:20 | Networking, Dinner, Sponsor Tables | All |
| 6:20-6:45 | Short Sponsor Presentations | Sponsors |
| 6:45-7:30 | Feature Presentation: “A Tale of Two Companies: Drug Discovery’s Best and Worst of Times” | Jim Hauske, President and Founder, Sensor Pharma (Bio) |
| 7:30-8:15 | Outsourcing/CRO Panel | Leslie Hickle,VP, Business Development,BioAtla, LLC (LinkedIn) Daniel Holsworth,Co-founder/Board of Directors, ODIN Therapeutics AS (LinkedIn) Richard Lin (Moderator),President and CEO, Explora BioLabs (LinkedIn) Ajay Madan, Senior Director of Development, Neurocrine Biosciences (LinkedIn) Scott Struthers, Founder & CSO, Crinetics Pharmaceuticals (LinkedIn) Diana Wetmore, Vice President of Business Development, Emerald BioStructures (Bio) |
| 8:15-9:00 | Networking, Sponsor Tables | All |
Sponsors
 |
 |
 |
 |
 |
 |
Our generous sponsors have provided the following promotions exclusive to event attendees, come for a chance to win!
Special Event Giveaways
- Millipore: $500 credit for Select Services
- Explora BioLabs: 1 free mouse or rat small molecule pharmacokinetic (PK) study free (worth ~$3500) per standard Explora 24 hr PK design protocol (including bioanalysis).
- Imgenex: 2 additional compounds added to screen of potential inflammatory and TLR agonists or antagonists using IMGENEX TLR/NF-κB SEAPorter™ HEK 293 stable cell lines. $5,000 value.
- BioTox Sciences: a free 3 day in-life Dog PK study, up to $4,500.00 in value (not including bioanalysis).
- Emerald BioStructures: iPad! ($500 value)
- GenScript: $500 off $3000 (or $1000 off $5000) service discount on non-molecular biology services.
If you want more details on the promotions, or have a promotion to offer to attendees, or want to sponsor contact us.
Event Details
Who: Biotechnology professionals in the greater San Diego area
What: San Diego Biotechnology Network July 19th Event:Virtual Biotech Part 1: How to Effectively Outsource a Drug Discovery Program
When: Tuesday, July 19th 2011, 5:30-9:00 p.m.
Where: Tango Del Rey, 3567 Del Rey Street, San Diego 92109 (Directions below)
Cost: $25 Standard/$20 Academic/$50 Recruiter, dinner provided, cash bar
Contact: http://sdbn.org/contact
For more information about the event: http://sdbn.org/july
Directions: From the North: South on Interstate 5, Exit Balboa Ave, Straight to 4th Traffic Light then left on Bunker Hill St. Building directly ahead 3 blks. From the South: North on Interstate 5, Exit Grand/ Garnet Ave, Straight to 3rd Traffic Light then right on Bunker Hill St. Building directly ahead 3 blks. Park on the street or in the structure just past (south of) Tango del Rey. DO NOT park in the Science Center lot.
Drug Discovery, Headline, SDBN Blog, SDBN Events »
SDBN June 21st Event Featuring aTyr Pharma | |
|
Posted by Mary Canady May 27th, 2011 .
| |
| No Comments |
The San Diego Biotechnology Network’s June 21st event will feature aTyr Pharma, with Board Member and CEO Jeffry Watkins (Bio) giving a talk titled “Innovation: Where is our Biology?” aTyr is developing therapeutics based on physiocrines, small proteins involved in signaling pathways for areas such hematology, immunology, and metabolism disorders. The company was founded based on research which originated at the Scripps Research Institute, and Watkins’ title indicates the company is reaching beyond in vitro drug discovery to focus on biological processes. It will be exciting to see the way this translational research is being carried out. Of course, there is always plenty of time for networking, register and join us June 21st!
Sponsors
|
 |
 |
Event Details
Who: Biotechnology professionals in the greater San Diego area
What: San Diego Biotechnology Network June 21st Event Featuring aTyr Pharma
When: Tuesday, June 21st 2011, 5:30-9:00 p.m.
Where: Tango Del Rey, 3567 Del Rey Street, San Diego 92109 (Directions below)
Cost: $25 Standard/$20 Academic/$50 Recruiter, dinner provided, cash bar
Contact: http://sdbn.org/contact
For more information about the event: http://sdbn.org/june
Directions: From the North: South on Interstate 5, Exit Balboa Ave, Straight to 4th Traffic Light then left on Bunker Hill St. Building directly ahead 3 blks. From the South: North on Interstate 5, Exit Grand/ Garnet Ave, Straight to 3rd Traffic Light then right on Bunker Hill St. Building directly ahead 3 blks. Park on the street or in the structure just past (south of) Tango del Rey. DO NOT park in the Science Center lot.
Drug Discovery, Headline, SDBN Events »
SDBN April 19th 2011 Event Featuring Celgene | |
|
Posted by Mary Canady March 22nd, 2011 .
| |
| No Comments |
Through research, acquisitions, and mergers, Celgene has built a robust product portfolio and pipeline in hematology and oncology. This accomplishment is quite a feat in today’s environment, with pharma pipelines dwindling, and they are one of the top ten fastest growing biotech stocks. Celgene has more than 4,000 employees worldwide, with important work being carried out at their San Diego location. David Webb, Vice President, Research & San Diego Site Director (Bio) will give a presentation titled “Celgene’s Drug Discovery Engine in San Diego” at our April 19th event.
As always, there will be plenty of time for networking, and we plan to do our ‘Introduce a Colleague’ activity which was very popular a few months ago. Sign up and we look forward to seeing you April 19th!
Sponsors
 |
 |
Contact us if you’d like to sponsor this event.
Event Details
Who: Biotechnology professionals in the greater San Diego area
What: San Diego Biotechnology Network April 19th Event Featuring Celgene
When: Tuesday, April 19th 2011, 5:30-9:00 p.m.
Where: Tango Del Rey, 3567 Del Rey Street, San Diego 92109 (Directions below)
Cost: $25/$20 Academic, dinner provided, cash bar
Contact: http://sdbn.org/contact
For more information about the event: http://sdbn.org/april
Directions: From the North: South on Interstate 5, Exit Balboa Ave, Straight to 4th Traffic Light then left on Bunker Hill St. Building directly ahead 3 blks. From the South: North on Interstate 5, Exit Grand/ Garnet Ave, Straight to 3rd Traffic Light then right on Bunker Hill St. Building directly ahead 3 blks. Park on the street or in the structure just past (south of) Tango del Rey. DO NOT park in the Science Center lot.
